Anke Biotechnology Announces IND Application for New Indication of PA3-17 Injection in Pediatric and Adolescent R/R T-ALL/LBL Accepted by NMPA

Gelonghux 12/4 | ANKEBIO announced that the clinical trial application for a new indication of PA3-17 injection, independently developed by its participating companies Bo sheng ji medicine science and technology (suzhou) co., LTD and Bo sheng ji Anke Cell Technology Co., Ltd, has been accepted. This new indication is "for children and adolescents with relapsed/refractory T lymphoblastic leukemia/lymphoma (R/R T-ALL/LBL)." The acceptance of this new indication’s clinical trial application represents only a stage achievement in new drug development. Whether it can obtain approval from the National Medical Products Administration to proceed with clinical trials and marketing still remains uncertain. Investors are advised to make decisions prudently and be mindful of investment risks.